Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331380

Institution ID

3331380

Institution full name and acronym

The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)

Institution countries

Spain

Institution role

Researcher

Institution website

ENCePP partner

No
Institution description
The Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (Fisabio) is a non-profit entity of a scientific and healthcare nature, whose primary purpose is the promotion, promotion and development of scientific-technical, health and biomedical in the Valencian Community. Fisabio integrates and manages the scientific activity of 18 health departments, and Fisabio-Public Health. It offers services to more than 1,500 professionals from the Valencian healthcare network, specialists who work on research projects and clinical trials managed through the Foundation. In addition, it coordinates the Valencian Network of Biobanks.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)
AIV - FISABIO Impact and risk of Herpes Zoster in immunosuppressed subjects in Valencia Region, Spain
An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU (COVID-19)
Assesing the Safety of Antihypertensive medication in Pregnancy (ASAP)
Case-control study based on hospitals about seasonal influenza vaccine effectiveness to avoid income associated with laboratory-confirmed influenza virus infection in subjects aged 18 or more during 2011-2020 seasons and the disease burden due to respiratory viruses in patients of any age admitted into the hospitals included in the study (AIV - Fisabio) (HBTNCC)
CONSIGN study: COVID-19 infection and medicines in pregnancy - a multinational registry based study
Demonstrating solutions for studying intermittent medication exposures in diseases with episodic manifestations during pregnancy: application to medication for migraine in pregnancy
Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International))
DRIVE - Brand-specific influenza vaccine effectiveness in Europe, season 2021/22 (DRIVE 2021/22)
Exposure to SSRI/SNRI and depression in pregnancy and long-term childhood outcomes: the effect of modifying factors
FINErenone druG Utilization Study and assessment of Temporal changes following availability of different treatment options in patients with chronic kidney disease and type 2 diabetes (FINEGUST)
HPV vaccines effectiveness to prevent genital warts in Valencia Region, Spain
id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe
id.DRIVE study of brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe
id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe
Impact of Rotavirus Vaccination on Acute Gastroenteritis outpatient and emergency department visits using “Real World Data” from the Valencia Region, Spain
mRNA-1273-P910: Clinical course, outcomes and risk factors of myocarditis and pericarditis following administration of Moderna vaccines targeting SARS-CoV-2.
Novel statistics to handle rare diseases and small sample sizes using Bayesian techniques: Application to Multiple Sclerosis (MS) and Systemic Lupus Erythematosus (SLE) in pregnancy
Opioids prescription in the Valencia Region: Patterns of Use, Misuse and Trends 2011-2017. A Population-based Real World Data Cohort
PATTERNS OF CLINICAL MANAGEMENT OF ASTHMATIC PATIENTS WITH EXACERBATIONS IN THE REAL-WORLD SETTING IN THE NATIONAL HEALTH SYSTEM
QALY loss due to respiratory syncytial virus (RSV) infection in children younger than 2 years and their relatives in the Valencian Community and Catalonia (AIV-Fisabio) (QALYs lost due to RSV)
Risk of Herpes Zoster in individuals diagnosed with COVID19 infection in the Valencia region of Spain: a retrospective cohort population-based study (AIV_HZ_2021_05_COVIDHZ_AOS)
SAFETY-VAC: a framework for the post-authorisation safety monitoring and evaluation of vaccines in the European Union (SAFETY-VAC)
SAFETY-VAC: Background incidence estimation of flares of pre-existing chronic diseases using pan-European electronic healthcare data sources. (SAFETY VAC)
Spatio-temporal impact of Rotavirus vaccine coverage on Rotavirus Hospitalizations in the Valencia Region, Spain
Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)
Studying drug exposure when disease is measured through accurate identification of an incident case: application to breast cancer in pregnancy (ConcePTION breast cancer demo)